SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001214659-20-003629
Filing Date
2020-04-22
Accepted
2020-04-22 17:18:02
Documents
2
Period of Report
2020-04-16

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT marketforms-48564.html 3  
1 PRIMARY DOCUMENT marketforms-48564.xml 3 5817
2 POA DOCUMENT poa.htm EX-24 3132
  Complete submission text file 0001214659-20-003629.txt   10336
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Issuer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O ALLOGENE THERAPEUTICS, INC. 210 E. GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address
Bhavnagri Veer (Reporting) CIK: 0001808980 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38693 | Film No.: 20808580